SATVI has conducted clinical trials of 5 new TB vaccine candidates, (6-8) in 11 different protocols.
The results of the trial of MVA85A, involving 2 797 infants, and conducted exclusively at SATVI, are expected to be available at the beginning of 2013.
As a principle, SATVI uses registration-standard vaccine trials to explore other critical areas in vaccine development.
An example of a very successful partnership is the TB Vaccine Site Network (TBVACSIN), spearheaded by SATVI academics, with support from the Aeras Foundation and the European Developing Countries Clinical Trials Partnership (EDCTP).
The aim of the first has been to develop a post-infection vaccine: the developed vaccine, H56, is currently in a clinical trial at SATVI.
SATVI has had a strong social commitment to the local authorities, by providing TB-specific training of health professionals and infrastructure development, and by donating equipment to health facilities and schools.
Multiple postgraduate students are training within SATVI.
As is the common experience of companies during rapid growth, SATVI has had to add structures on a relatively ad hoc basis from 2001 to 2011, to meet ever-increasing demands with the risk, however, of a loss of efficiency.
SATVI has made major contributions to TB vaccine development, and is committed to continue to work to achieve 'A World Without TB'.
The authors acknowledge contributions of every SATVI member, from 2001 to the present: our achievements would not have been possible without their superb commitment.
The main objectives of the SATVI, a research unit within the Institute of Infectious Diseases and Molecular Medicine at UCT, are to develop the capacity of our rural site in Worcester to do phase I to phase IV TB vaccine trials, to determine important epidemiological characteristics that are of relevance to TB in the area and to identify clinical, microbiological and immunological endpoints of key importance to all stages of vaccine trials.
The work of SATVI is supported by a number of international donors including the Aeras Global TB Vaccine Foundation, the National Institutes for Heath, USA, the European Union and the Welcome Trust.